RHOA and rhabdomyosarcoma: Rapamycin has been shown to reduce Rho-A expression and activation via mTORC1 inhibition and subsequent reduction in S6 kinase and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) activity to reduce cytoskeletal rearrangement in human rhabdomyosarcoma and Ewing sarcoma cell lines [33].